Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is intended solely for the introduction of medications related to medical health and does not recommend treatment plans (if involved); it does not represent the platform’s position.Authorization is required for any article reprints.
On July 2, iRegene Therapeutics Co., Ltd. (hereinafter referred to as “iRegene Therapeutics”) announced the completion of its C+ round financing amounting to RMB 260 million. This round was led by Chengdu Sci-Tech Innovation Investment, with joint investments from CSC Financial Capital, Wuxi Venture Capital Group, Dingtai Star, Nanjing Xinjiye, and Hony Capital, among others. Existing shareholders Yuanxi Haihe and GSR United Runpuyuanfeng continued to make additional investments.
The proceeds from this round of financing will be primarily used to advance the company’s core clinical pipeline, conduct multi-pipeline clinical development, support global regulatory registration and clinical operations, build out industrialization capabilities, and facilitate subsequent capitalization efforts.
This marks another significant financing round completed by iRegene Therapeutics in a short period, following its C1 round of RMB 210 million secured in June this year.The cumulative funding amount across two rounds reached RMB 470 million.The rapid completion of two consecutive financing rounds fully demonstrates the capital market’s continued recognition of iRegene Therapeutics’ core clinical assets, multi-pipeline layout, industrialization foundation, and subsequent capitalization path.A representative from iRegene Therapeutics stated, “The completion of two consecutive financing rounds within a single month marks a significant milestone in the company’s development. Moving forward, the company will leverage more efficient execution, a clearer path to commercialization, and a more robust clinical development strategy to propel China’s original cell therapies onto the international stage.”
iRegene Therapeutics has established a comprehensive product portfolio, covering two high-demand sectors: neurodegenerative diseases of the central nervous system and rare ophthalmic diseases.iRegene Therapeutics' focus on Parkinson's diseaseNouvNeu001: A Universal iPSC-Derived Dopaminergic Neural Progenitor Cell Therapeutic ProductIt is the company's core asset with the most advanced clinical progress and the highest attention from the capital market. In the field of central nervous system diseases, the companyNouvNeu004 Developed for Multiple System Atrophy, Parkinsonian TypeThe company has entered the clinical development stage. In the field of ophthalmic diseases, it has established the NouvSight pipeline portfolio focused on irreversible visual impairment and retinal degenerative diseases, initially forming a product combination of “core clinical assets + subsequent clinical pipelines + potential expansion into major indications.”The simultaneous advancement of multiple pipelines into clinical development fully validates the replicability of iRegene Therapeutics’ “AI + Chemically Induced” platform technology, while also enabling the company to build a multi-layered clinical asset portfolio, thereby diversifying the R&D risks associated with individual projects.iRegene Therapeutics’ management stated that, following the completion of this C+ round of financing, the company will focus on three core tasks: releasing clinical data, iterating its technology platform, and refining its industrialization system. It will continue to advance global clinical development and overseas regulatory registrations, while deepening international industrial collaborations. In the future, leveraging China’s original “AI + chemical induction” iPSC technology, iRegene Therapeutics aims to build a globally leading innovative platform for cell therapy, enabling more patients with refractory diseases to benefit from cell therapy drugs originating in China.As its capitalization process accelerates, this Chengdu-based, globally oriented Chinese benchmark enterprise in cell therapy is poised to list on international capital markets in the near future. It is expected to become a flagship company marking the transition of China’s iPSC industry from technological innovation to commercial success, leading the domestic cell therapy sector into a new phase of high-quality development.References:
iRegene Therapeutics Official Website
Scan the QR code to join the groupMastering CAR-T therapy, stem cell therapy, and geneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
